At Merck, we're dedicated to making a difference in people's lives and working to help the world be well.

For people living with HIV, this means providing greater access to care and educational programs, as well as supporting research efforts and developing lasting partnerships that will help battle the disease.

Roll over each photo to learn more about the HIV epidemic and what Merck is doing.

Access to Care

Collaboration is a hallmark of the progress made against HIV. See how Merck's commitment to improving patient access is helping in the global fight. Learn more.

AIDS Memorial Quilt

Through quilt-making and educational workshops, we're working with the HIV community to foster healing, raise awareness and inspire action in the struggle against HIV. Learn more.

A Design for Living with HIV

Merck's commitment to HIV includes helping to educate patients on how to talk to their doctors. I Design helps people to have that conversation and tailor a treatment plan with their physician. Learn more.

Our Unwavering Commitment

For 25 years Merck has supported HIV/AIDS research, care access and partnerships around the world. Watch the video.

Supporting HIV Care Access in the U.S.

The Merck Company Foundation is committing $3 million to help connect HIV-positive people in three U.S. cities to effective, comprehensive healthcare. Learn more about the HIV Care Collaborative.

Twenty-five Years of Research, Access and Partnerships

We are committed to the long-term battle against this disease. Learn more about our global partnerships.

HIV Fact

More than one million people in the U.S. are living with HIV infection, with approximately 50,000 new HIV infections diagnosed each year.

Merck HIV/AIDS Partnership in China

The China-MSD HIV/AIDS Partnership (C-MAP) is an award-winning program to increase awareness of HIV/AIDS, and strengthen prevention, treatment and support for those affected in the country. Learn more.

HIV Fact

Of the estimated 15 million people living with HIV in low- and middle-income countries, in 2011, 8 million had access to treatment.